Herpes simplex virus type 1 replication (HSV-1 replication)

Herpes simplex virus type 1 (HSV-1) replication is the multi-step biological process by which the virus produces progeny within host cells, primarily involving the synthesis of viral DNA in the nucleus (StatPearls, 2023). This process is orchestrated by a suite of viral proteins, most notably the DNA-directed DNA polymerase (UL30), the helicase-primase complex (UL5/UL8/UL52), and the viral thymidine kinase (UL23) (UniProt, 2024; NCBI Bookshelf, 1996). Therapeutic intervention typically focuses on these specific enzymes to halt viral proliferation and reduce clinical symptoms associated with infections like herpes labialis and encephalitis (Journal of Virology, 2018). Most standard-of-care drugs, such as acyclovir and valacyclovir, are nucleoside analogs that require activation by viral thymidine kinase to subsequently inhibit the viral DNA polymerase through competitive inhibition and chain termination (PubChem, 2024). While "replication" describes the overall pathway, drug development specifically targets these individual molecular components to achieve high selectivity and minimize host cell toxicity (Nature Reviews Microbiology, 2020).

Other names

HSV-1 replication cycleHSV-1 DNA synthesisHSV-1 lytic cycleHerpes simplex virus 1 viral cycleHSV-1 replication machinery

Inhibition of viral DNA polymerase through competitive inhibition with dGTP and subsequent DNA chain termination; inhibition of the viral helicase-primase complex preventing DNA unwinding; pyrophosphate analog competition inhibiting viral DNA synthesis.